MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage.
Antineoplastic Agents
/ administration & dosage
Apoptosis
/ drug effects
Cell Death
/ drug effects
Cell Line, Tumor
Cell Survival
/ drug effects
DNA Damage
/ drug effects
DNA Fragmentation
/ drug effects
Dacarbazine
/ administration & dosage
Glutathione
/ metabolism
Humans
Melanoma
/ drug therapy
Mitochondrial Membranes
/ drug effects
Myeloid Cell Leukemia Sequence 1 Protein
/ antagonists & inhibitors
Skin Neoplasms
/ drug therapy
BH3 mimetic
MIM1
Mcl-1 protein
apoptosis
dacarbazine
malignant melanoma
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
23
11
2018
revised:
02
08
2019
accepted:
09
08
2019
pubmed:
15
8
2019
medline:
24
10
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Malignant melanoma is a high aggressive malignancy in humans and causes 60-80% of deaths from skin cancer. Defect in an intrinsic pathway of apoptosis via overexpression of Mcl-1 is responsible for malignant melanoma development and progression, and also for resistance to chemotherapeutic agents. MIM1 is a specific low molecular Mcl-1 protein inhibitor that is able to induce Mcl-1-dependent cancer cells death. Here, we examined the effect of MIM1 as well as MIM1 and dacarbazine (DTIC) mixture on cell viability, apoptosis, and cell cycle progression in COLO829 melanoma cells. Cell viability was performed by the WST-1 assay. Analysis of apoptosis as well as cell cycle progression was determined by fluorescence image cytometer NucleoCounter NC-3000. The obtained results demonstrated that the MIM1 exhibited high cytotoxicity against melanotic melanoma cells and induced mitochondrial membrane breakdown, GSH depletion, and DNA fragmentation. Additionally, MIM1 enhanced the proapoptotic effect of DTIC toward melanoma cells; furthermore, a mixture of these drugs caused cell cycle arrest at G2/M phase in COLO829 cells. Taken together, these data provide, for the first time, evidence that a low molecular weight Mcl-1 inhibitor-MIM1 may be a promising agent with antitumor and proapoptotic properties toward melanoma cells.
Substances chimiques
Antineoplastic Agents
0
MCL1 protein, human
0
Myeloid Cell Leukemia Sequence 1 Protein
0
Dacarbazine
7GR28W0FJI
Glutathione
GAN16C9B8O
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20-31Subventions
Organisme : Medical University of Silesia
ID : KNW-1-037/K/9/O
Organisme : Medical University of Silesia
ID : KNW-2-031/D/8/N
Informations de copyright
© 2019 Société Française de Pharmacologie et de Thérapeutique.
Références
Erdei E., Torres S.M. A new understanding in the epidemiology of melanoma. Expert Rev. Anticancer Ther. (2010) 10 1811-1823.
Bandarchi B., Jabbari C.A., Vedadi A., Navab R. Molecular biology of normal melanocytes and melanoma cells. J. Clin. Pathol. (2013) 66 644-648.
Bhatia S., Tykodi S.A., Thompson J.A. Treatment of metastatic melanoma: an overview. Oncology (2009) 23 488-496.
Garbe C., Peris K., Hauschild A., et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2016. Eur. J. Cancer (2016) 63 201-217.
Quillet A., Colin O., Bourgeois N., et al. Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database. Fundam. Clin. Pharmacol. (2018) 32 227-233.
Hassan M., Watari H., AbuAlmaaty A., Ohba Y., Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed. Res. Int. (2014) 2014 1-24.
Zhao Y., He J., Li J., et al. Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells. Cell Death Dis. (2017) 8 e3133.
Mohana-Kumaran N., Hill D.S., Allen J.D., Haass N.K. Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy. Pigment Cell Melanoma Res. (2014) 27 525-539.
Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene (2007) 26 1324-1337.
Billiard C. BH3 mimetics: status of the field and new developments. Mol. Cancer Ther. (2013) 12 1691-1700.
Shamas-Din A., Brahmbhatt H., Leber B., Andrews D.W. BH3-only proteins: orchestrators of apoptosis. Biochim. Biophys. Acta. (2011) 1813 508-520.
Delbridge A., Strasser A..The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. (2015) 22 1071-1080.
Hata A.N., Engelman J.A., Faber A.C..The BCL2 family: key mediators of the apoptotic response to targeted anticancer therapeutics. Cancer Discov. (2015) 5 475-487.
Mukherjee N., Lu Y., Almeida A., et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget (2017) 8 46801-46817.
Boisvert-Adamo K., Longmate W., Abel E.W., Aplin A.E. Mcl-1 is required for melanoma cell resistance to anoikis. Mol. Cancer Res. (2009) 7 549-556.
Eberle J., Hossini A.M. Expression and function of Bcl-2 proteins in melanoma. Curr. Genomics (2008) 9 409-419.
Quinn B.A., Dash R., Azab B., et al. Targeting Mcl-1 for the therapy of cancer. Expert. Opin. Investig. Drugs (2011) 20 1397-1411.
Cohen N.A., Stewart M.L., Gavathiotis E., et al. A competitive stapled peptide screen identifies a selective small molecule that overcomes Mcl-1-dependent leukemia cell survival. Chem. Biol. (2012) 19 1175-1186.
Kritzer J.A. The secret of MIM: a novel, Mcl-1-specific small molecule. Chem. Biol. (2012) 19 1082-1083.
Respondek M., Beberok A., Rok J., Rzepka Z., Wrześniok D., Buszman E. MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells. Toxicol. In Vitro (2018) 53 126-135.
Thallinger C., Wolschek M., Wacheck V., et al. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J. Invest. Dermatol. (2003) 120 1081-1086.
Lucas K.M., Mohana-Kumaran N., Lau D., et al. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin. Cancer Res. (2012) 18 783-795.
Wroblewski D., Jiang C.C., Croft A., Farrelly M.L., Zhang X.D., Hersey P. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PLoS ONE (2013) 8 e84073.
Kelly P.N., Strasser A..The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ (2011) 18 1414-1424.
Senft D., Berking C., Graf S.A., Kammerbauer C., Ruzicka T., Besch R. Selective Induction of cell death in melanoma cell lines through targeting of Mcl-1 and A1. PLoS ONE (2012) 7 e30821.
Circu M.L., Aw T.Y. Glutathione and modulation of cell apoptosis. Biochim. Biophys. Acta (2012) 1823 1767-1777.
Nicola M.D., Ghibelli L. Glutathione depletion in survival and apoptotic pathways. Front. Pharmacol. (2014) 5 1-4.
Beberok A., Wrześniok D., Szlachta M., et al. Lomefloxacin induces oxidative stress and apoptosis in COLO829 melanoma cells. Int. J. Mol. Sci. (2017) 18 1-18.
Barnum K.J., O'Connell M.J..Cell cycle regulation by checkpoints. Methods Mol. Biol. (2014) 1170 29-40.
Pucci B., Kasten M., Giordano A. Cell cycle and apoptosis. Neoplasia (2000) 2 291-299.
Stark G.R., Taylor W.R. Analyzing the G2/M checkpoint. Methods Mol. Biol. (2004) 280 51-82.
Varadarajan S., Vogler M., Butterworth M., Dinsdale D., Walensky L.D., Cohen G.M. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. (2013) 20 1475-1484.
Cabel L., Blanchet B., Thomas-Schoemann A., et al. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam. Clin. Pharmacol. (2018) 32 98-107.